Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes: The LAMP Randomized Clinical Trial
Primary result · Stroke recurrenceResult — go to the resultHazard ratio 0.56 95% CI 0.34–0.91Authors' conclusion
The trial results suggest that among Chinese patients with T2D and minor AIS or high-risk TIA, liraglutide treatment might reduce stroke recurrence and improve 90-day outcomes. However, given the underpowered nature of the study, these findings should be interpreted with caution.
Study context
- Population
- Patients with T2D and minor acute ischemic stroke (NIHSS ≤3) or high-risk transient ischemic attack (TIA) (ABCD2 ≥4), randomized within 24 hours of symptom onset; 27 hospitals in China; median age 63.5 years, 36.3% femalerandomized
- Participants
- 636 patients
- Comparison
- Liraglutide plus standard treatment vs standard treatment
- Primary endpoint
- Stroke recurrence (ischemic or hemorrhagic)
- Follow-up
- 90 days
Methodological detailsmulticenter, prospective, open-label, blinded end point, 27 hospitals in China, June 25, 2019 to December 27, 2023; final follow-up March 24, 2024
- Multicenter
- Prospective
- Open-label
- Blinded end point
- 27 hospitals in China, June 25, 2019 to December 27, 2023; final follow-up March 24, 2024
Primary result
Stroke recurrence
Hazard ratio
0.56
95% CI 0.34–0.91
P = 0.02
Events by treatment group
Liraglutidevs Control
HR 0.56 (95% CI 0.34–0.91); P = 0.02
As reported in the abstract
Further findings
| Outcome | Liraglutide | Control | OR (95% CI) | P value | |
|---|---|---|---|---|---|
| Excellent functional outcome (modified Rankin Scale score ≤1) | 87.3% | 77.8% | 1.95 (1.28–3.00) | P = 0.002 | |
| 0.20.5125Odds ratio (log scale) |
Safety
Symptomatic intracranial hemorrhage and all-cause mortality · 90 days
- Rates of symptomatic intracranial hemorrhage and all-cause mortality were low and similar between groups
Original publication
Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes: The LAMP Randomized Clinical Trial. JAMA Intern Med. Published 1 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →